A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
← catalyst calendarNCT05920356 · readout in 315 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
750estimated
Sites
412
Countries
Argentina, Australia, Austria +35
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-16 | actual | When the study began enrolling |
| Primary completion | 2027-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-06-29 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer (NSCLC)
Interventions
- Drug: Sotorasib — also filed as AMG 510, LUMYKRAS ®, LUMAKRAS ®
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFProgression-free Survival (PFS)
measured Approximately 2.5 years
Overall Survival (OS)
measured Approximately 2.5 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed